Possible contributions of thyroid hormone replacement to specific behaviors of cancer

Aleck Hercbergs; Paul J. Davis; Hung Yun Lin; Shaker A. Mousa

doi:10.1016/j.biopha.2016.09.053

Possible contributions of thyroid hormone replacement to specific behaviors of cancer

Aleck Hercbergs
, Paul J. Davis
, Hung Yun Lin
, Shaker A. Mousa

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

Abstract

L-Thyroxine (T₄) is the principal replacement hormone for patients who have hypothyroidism. Some preclinical and clinical evidence supports the possibility that T₄ can at least permissively affect certain features of established cancers and cancer-relevant angiogenesis. Thus, in the occasional patient with hypothyroidism and concomitant cancer, it appears reasonable to consider thyroid hormone replacement exclusively with 3,3′,5-triiodo-L-thyronine (T₃). This use of T₃ has been shown to be effective and safe in early experience with medical induction of euthyroid hypothyroxinemia in patients with advanced solid tumors.

Original language	English
Pages (from-to)	655-659
Number of pages	5
Journal	Biomedicine and Pharmacotherapy
Volume	84
DOIs	https://doi.org/10.1016/j.biopha.2016.09.053
Publication status	Published - Dec 1 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

3,3′,5-Triiodo-L-thyronine (T)
Angiogenesis
Apoptosis
Hypothyroidism
L-Thyroxine (T)
Thyroid cancer
Tyrosine kinase inhibitor (TKI)

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1016/j.biopha.2016.09.053

Cite this

@article{a441fd71c0f34aae89d7baf756e1bad6,

title = "Possible contributions of thyroid hormone replacement to specific behaviors of cancer",

abstract = "L-Thyroxine (T4) is the principal replacement hormone for patients who have hypothyroidism. Some preclinical and clinical evidence supports the possibility that T4 can at least permissively affect certain features of established cancers and cancer-relevant angiogenesis. Thus, in the occasional patient with hypothyroidism and concomitant cancer, it appears reasonable to consider thyroid hormone replacement exclusively with 3,3′,5-triiodo-L-thyronine (T3). This use of T3 has been shown to be effective and safe in early experience with medical induction of euthyroid hypothyroxinemia in patients with advanced solid tumors.",

keywords = "3,3′,5-Triiodo-L-thyronine (T), Angiogenesis, Apoptosis, Hypothyroidism, L-Thyroxine (T), Thyroid cancer, Tyrosine kinase inhibitor (TKI)",

author = "Aleck Hercbergs and Davis, \{Paul J.\} and Lin, \{Hung Yun\} and Mousa, \{Shaker A.\}",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Masson SAS",

year = "2016",

month = dec,

day = "1",

doi = "10.1016/j.biopha.2016.09.053",

language = "English",

volume = "84",

pages = "655--659",

journal = "Biomedicine and Pharmacotherapy",

issn = "0753-3322",

publisher = "Elsevier Masson s.r.l.",

}

TY - JOUR

T1 - Possible contributions of thyroid hormone replacement to specific behaviors of cancer

AU - Hercbergs, Aleck

AU - Davis, Paul J.

AU - Lin, Hung Yun

AU - Mousa, Shaker A.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - L-Thyroxine (T4) is the principal replacement hormone for patients who have hypothyroidism. Some preclinical and clinical evidence supports the possibility that T4 can at least permissively affect certain features of established cancers and cancer-relevant angiogenesis. Thus, in the occasional patient with hypothyroidism and concomitant cancer, it appears reasonable to consider thyroid hormone replacement exclusively with 3,3′,5-triiodo-L-thyronine (T3). This use of T3 has been shown to be effective and safe in early experience with medical induction of euthyroid hypothyroxinemia in patients with advanced solid tumors.

AB - L-Thyroxine (T4) is the principal replacement hormone for patients who have hypothyroidism. Some preclinical and clinical evidence supports the possibility that T4 can at least permissively affect certain features of established cancers and cancer-relevant angiogenesis. Thus, in the occasional patient with hypothyroidism and concomitant cancer, it appears reasonable to consider thyroid hormone replacement exclusively with 3,3′,5-triiodo-L-thyronine (T3). This use of T3 has been shown to be effective and safe in early experience with medical induction of euthyroid hypothyroxinemia in patients with advanced solid tumors.

KW - 3,3′,5-Triiodo-L-thyronine (T)

KW - Angiogenesis

KW - Apoptosis

KW - Hypothyroidism

KW - L-Thyroxine (T)

KW - Thyroid cancer

KW - Tyrosine kinase inhibitor (TKI)

UR - https://www.scopus.com/pages/publications/84988965478

UR - https://www.scopus.com/pages/publications/84988965478#tab=citedBy

U2 - 10.1016/j.biopha.2016.09.053

DO - 10.1016/j.biopha.2016.09.053

M3 - Review article

C2 - 27697637

AN - SCOPUS:84988965478

SN - 0753-3322

VL - 84

SP - 655

EP - 659

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

ER -

Possible contributions of thyroid hormone replacement to specific behaviors of cancer

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this